Details of Disease

General Information of Disease (ID: DIS9LQVD)

Disease Name	Articular cartilage disorder
Synonyms	disorder of articular cartilage; articular cartilage disorder of upper arm; articular cartilage disorder of the pelvic region and thigh; articular cartilage disorder of shoulder region; articular cartilage disorder of multiple sites; articular cartilage disorder of hand; articular cartilage disorder of forearm; articular cartilage disorder of ankle and/or foot; articular cartilage disorder involving upper arm; articular cartilage disorder involving shoulder region; articular cartilage disorder involving pelvic region and thigh; articular cartilage disorder involving multiple sites; articular cartilage disorder involving hand; articular cartilage disorder involving forearm; articular cartilage disorder involving ankle and foot; disorder of articular cartilage of joint; disease or disorder of articular cartilage of joint; disease of articular cartilage of joint; articular cartilage of joint disease or disorder; articular cartilage of joint disease; articular cartilage disorder
Disease Class	FA34: Joint derangement
Definition	A disease involving the articular cartilage of joint.
Disease Hierarchy	DISWD40R: Disease DISVEERK: Arthropathy DIS9LQVD: Articular cartilage disorder
ICD Code	ICD-11 ICD-11: FA34.Y
Disease Identifiers	MONDO ID MONDO_0003816 UMLS CUI C0158073 MedGen ID 510440 SNOMED CT ID 53417006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bupivacaine	DM4PRFC	Approved	Small molecular drug	[1]
Carticel	DMJEUFA	Approved	NA	[2]
Chondrocelect	DMWIM88	Approved	NA	[2]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[3]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MACI	DMS3SPV	Phase 3	NA	[4]
Recombinant human cartilage-derived retinoic acid-sensitive protein depot	DMLCCGO	Phase 2/3	NA	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AA-166	DM2BMAZ	Investigative	NA	[6]
Tissuegene-Cs	DM3337H	Investigative	NA	[7]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	Bupivacaine FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Dexamethasone FDA Label
4	Clinical pipeline report, company report or official report of Sanofi.
5	ClinicalTrials.gov (NCT00450203) Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer. U.S. National Institutes of Health.
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794).
7	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.